One‐Year Substantia Nigra R2* Changes across Parkinson's Disease Stages

Abstract Background Magnetic resonance imaging (MRI) relaxometry using measurement is a promising non‐invasive marker of brain iron‐related changes in Parkinson's disease (PD). Although longitudinal susceptibility MRI studies have demonstrated progression over time, the stage‐dependent dynamics of changes across the full spectrum of PD duration remain incompletely characterized. Objectives The goal was to assess 1‐year longitudinal changes across PD stages within a multicenter framework, compared with healthy controls (HC). Methods In this prospective multicenter study, 95 PD patients and 65 age‐ and sex‐matched HC underwent 3 T MRI and clinical evaluation at baseline and 1 year. PD patients were stratified by disease duration (<5, 5–10, 10–15, >15 years). values were extracted from basal ganglia regions, focusing primarily on the substantia nigra (SN). Motor and non‐motor assessments, performed in the on ‐medication state, included the Movement Disorder Society‐Unified Parkinson's Disease Rating Scale, Montreal Cognitive Assessment, and mood/apathy scales. Results SN increased significantly over 1 year across PD patients (+5% within‐group) and HC (+2% within‐group), resulting in a +3% greater longitudinal change in PD versus HC ( P < 0.001). Larger SN changes were observed in patients with longer disease duration ( r = 0.28; P = 0.006). Significant changes were also detected in other basal ganglia regions. No significant change in motor or non‐motor disability in the on ‐medication state was observed over 1 year. Conclusions S N increased over 1 year in PD across disease stages, with larger changes in more advanced patients and no evidence of an early plateau. These findings support the potential of as a sensitive imaging marker of PD progression over short intervals. © 2026 International Parkinson and Movement Disorder Society.

Authors

Institutions

Publication Details

Journal
Movement Disorders
Published
2026-04-27
DOI
https://doi.org/10.1002/mds.70331
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

One‐Year Substantia Nigra R2* Changes across Parkinson's Disease Stages

Nicolas Carrière, Anne Doé de Maindreville, M Vidailhet, Christian Gény et al.
Movement Disorders
Parkinson's Disease Mechanisms and Treatments
article

One‐Year Substantia Nigra R2* Changes across Parkinson's Disease Stages

Nicolas Carrière, Anne Doé de Maindreville, M Vidailhet, Christian Gény, J.-M. Bonny, Carine Chassain, Patrice Péran, Isabelle Bénatru, Jean Luc Houeto, Wassilios G. Meissner, Thomas Boraud, Olivier Colin, S Lehericy, Calvin Coussedière, Elodie Durand, MPI‐ R 2 * $$ {\mathrm{R}}_2^{\ast } $$ study group, Solène Frismand, Fabienne Ory‐Magne, Bruno Pereira, David Devos, Ana Marques, Stéphane Thobois, Luc Defebvre, Jean‐Christophe Corvol, Philippe Remy, Olivier Rascol, Elena Moro, Franck Durif, Christine Brefel‐Courbon, Emmanuelle Schmitt
article en

Abstract

Abstract Background Magnetic resonance imaging (MRI) relaxometry using measurement is a promising non‐invasive marker of brain iron‐related changes in Parkinson's disease (PD). Although longitudinal susceptibility MRI studies have demonstrated progression over time, the stage‐dependent dynamics of changes across the full spectrum of PD duration remain incompletely characterized. Objectives The goal was to assess 1‐year longitudinal changes across PD stages within a multicenter framework, compared with healthy controls (HC). Methods In this prospective multicenter study, 95 PD patients and 65 age‐ and sex‐matched HC underwent 3 T MRI and clinical evaluation at baseline and 1 year. PD patients were stratified by disease duration (<5, 5–10, 10–15, >15 years). values were extracted from basal ganglia regions, focusing primarily on the substantia nigra (SN). Motor and non‐motor assessments, performed in the on ‐medication state, included the Movement Disorder Society‐Unified Parkinson's Disease Rating Scale, Montreal Cognitive Assessment, and mood/apathy scales. Results SN increased significantly over 1 year across PD patients (+5% within‐group) and HC (+2% within‐group), resulting in a +3% greater longitudinal change in PD versus HC ( P < 0.001). Larger SN changes were observed in patients with longer disease duration ( r = 0.28; P = 0.006). Significant changes were also detected in other basal ganglia regions. No significant change in motor or non‐motor disability in the on ‐medication state was observed over 1 year. Conclusions S N increased over 1 year in PD across disease stages, with larger changes in more advanced patients and no evidence of an early plateau. These findings support the potential of as a sensitive imaging marker of PD progression over short intervals. © 2026 International Parkinson and Movement Disorder Society.

Movement Disorders
Université Claude Bernard Lyon 1 (FR), Centre National de la Recherche Scientifique (FR), Université Toulouse III - Paul Sabatier (FR), Université de Bordeaux (FR), Inserm (FR), Université Fédérale de Toulouse Midi-Pyrénées (FR), Université Paris-Est Créteil (FR), Université de Montpellier (FR), Université de Lille (FR), Centre Hospitalier Universitaire de Grenoble (FR), Centre Hospitalier Universitaire de Lille (FR), Université de Poitiers (FR), Sorbonne Université (FR), Institut des Maladies Neurodégénératives (FR), Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR), Centre Hospitalier Universitaire de Montpellier (FR), Centre de Recherche en Neurosciences de Lyon (FR), Skive Hospital (DK), New Zealand Brain Research Institute (NZ), Centre Hospitalier Régional et Universitaire de Nancy (FR), University of Clermont Auvergne (FR), Hôpital Pierre Wertheimer (FR), Centre Hospitalier Universitaire de Reims (FR), Centre Hospitalier Universitaire de Poitiers (FR), Centre Hospitalier Universitaire de Clermont-Ferrand (FR), Unité Mixte de Recherche sur les Herbivores (FR), Grenoble Institute of Neurosciences (FR), Institut du Cerveau (FR), Institut Mondor de Recherche Biomédicale (FR), Université de Limoges (FR), Université Grenoble Alpes (FR), Université de Reims Champagne-Ardenne (FR)
Association France Parkinson
Openalex Percentile: Top 5%
Parkinson's Disease Mechanisms and Treatments
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.